“Rising Preference for Long-Acting and Species-Specific Pain Management”
- A significant and accelerating trend in the global veterinary NSAIDs market is the growing preference for long-acting and species-specific formulations tailored to the unique physiological needs of companion and livestock animals. This evolution in treatment practices is significantly improving therapeutic outcomes and compliance
- For instance, Galliprant (grapiprant) is designed specifically for dogs, offering targeted osteoarthritis relief with a lower risk of gastrointestinal side effects compared to traditional NSAIDs. Similarly, Equioxx is a once-daily NSAID exclusively formulated for horses, highlighting the industry's shift toward animal-specific pain solutions
- Long-acting NSAIDs help reduce dosing frequency, enhancing convenience for pet owners and ensuring consistent pain control in chronic conditions such as arthritis and post-surgical recovery. Palatable, chewable tablet formulations further improve compliance and user satisfaction
- In livestock, the increasing use of NSAIDs such as meloxicam during routine procedures such as dehorning or castration reflects heightened awareness of animal welfare and regulatory encouragement for humane treatment
- The move toward more targeted, effective, and longer-lasting NSAID therapies is reshaping veterinary pain management standards. As a result, pharmaceutical companies are focusing on developing innovative delivery systems and safer formulations to meet the rising demand for advanced veterinary care solutions
